In the Chinese stock market, where concept is popular, precision medicine is an excellent subject that the market will not miss. From the end of January 2015, Obama proposed the "precision medicine" program in the United States, but only two years ago, traditional listed companies have also stepped into this field. "Precise medicine represents the development direction of medicine, and the capital market is optimistic about this industry. Listed companies are also willing to develop precision medicine through mergers and acquisitions and opening up some business by themselves." Investment industry "medicine brother" Hui Tianfu Zhou Rui recently BIO4P, 2016 Precision Medical Innovation Forum, said in an interview with the first financial reporter. In this issue, Gene Tao has sorted out more than 30 companies involved in the concept of precision medical care in A-share listed companies. It is found that equity participation or mergers and acquisitions is the main way for listed companies to deploy precision medical treatment. The direction of entry involves many links in the precision medical industry chain. The precision medical industry itself is still in the early stage of development, and it cannot bring profits to listed companies in the short term. After two years of heat, the story dividend of precision medical treatment is nearing the end of the first stage. In the next two or three years, the precision medical field will enter the merger. High incidence. The layout of listed companies has not yet become a system The American Precision Medicine Program is in line with the Human Genome Project. The completion of the Human Genome Project laid the foundation for precision medicine and the development of the genetic industry. Since 2011, with the significant reduction in sequencing costs and the commercialization of non-invasive prenatal genetic testing, the genetic industry has embarked on a path of development. But the industry is so young that the industry leader, Huada Gene, submitted its prospectus a year ago, waiting for the listing review by the Securities and Futures Commission. Berry and Kang, which was established in 2010, also took the opportunity to review the Tianxing instrument in August this year, with the speed of overtaking at the corner and the Huada Gene Station on the same starting line. Undoubtedly, more companies will put the landing capital market on the agenda in the next two or three years, and traditional listed companies have already begun to deploy in the direction of precision medicine. According to the rough statistics of the First Financial Reporter, there are at least 30 listed companies involved in the concept of precision medical care in A-shares. The layout direction involves many links in the precision medical industry chain, such as sequencing instrument development and consumables, fully automated POCT molecular diagnostics, and third parties. Independent medical laboratory, etc. Gene sequencing services such as non-invasive prenatal genetic testing, deafness genetic testing, etc., and the most popular areas are liquid biopsy and cell immunotherapy for tumor diagnosis and treatment. Zhou Rui said that the concept of precision medicine is relatively new. Most of the pure precision medical companies are in the stage of business model exploration. The same is true in the United States. The company based on second-generation sequencing in cancer diagnosis and prevention is only doing a good job in a specific direction. There is no system. From the specific operation of listed companies, most companies focus on gene sequencing services and cell therapy in precise layout, and the development of sequencers is relatively rare. In terms of time, most companies are involved in precision medicine from 2015 to 2016, and the harvest period is still far away. In the research and development of sequencing instruments, Zixin Pharmaceutical and the Beijing Genomics Institute of the Chinese Academy of Sciences jointly developed domestically produced sequencers, but they have not yet been mass-produced. The company also announced in January 2016 that it will jointly build a high-throughput semiconductor sequencer with Shanghai Xiaohaituo Technology Co., Ltd., and jointly own a 15% stake in Xiaohaituo Technology. In addition, Shandong Haihua has established a holding subsidiary in the development and sales of biochips. In terms of gene big data, Rongzhilian relies on the “Bio Cloud†of Huada's gene distribution. Rongzhilian designs, builds and maintains the Bioinformatics Supercomputing Center in Shenzhen and Hong Kong for Huada Gene. Fruit juice drinks is a beverage made of fruit juice products obtained by physical methods such as pressing, centrifugation and extraction. Fruit juice retains most of the nutrients in the fruit, such as vitamins, minerals, sugar and pectin in dietary fiber. Often drinking fruit juice can help digestion, moisten the intestines and supplement the lack of nutrients in the diet. Juice Drinks,Honey Tea,Honey Citron Tea,Goji Berry Juice Xi'an Gawen Biotechnology Co., Ltd , https://www.seoagolyn.com
There are two kinds of fruit juice: pure fruit juice and compound fruit juice. As far as pure fruit juice is concerned, it can be divided into two types: one is to directly use the original juice, and the other is to dehydrate the freshly squeezed fruit juice first, and then add water to reduce it into concentrated fruit juice. Most pure fruit juices are concentrated. AGOLYN offers various flavors of honey tea, such as honey Citron tea etc.